Ensysce Biosciences Company Insiders
| ENSCW Stock | USD 0 0 42.50% |
Ensysce Biosciences employs about 6 people. The company is managed by 6 executives with a total tenure of roughly 14 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Recap of Ensysce Biosciences' management performance can provide insight into the venture performance.
| Geoff Birkett Insider Chief Officer |
| MSE MBA Insider Chief Officer |
Ensysce |
Ensysce Biosciences Management Team Effectiveness
Ensysce Biosciences' management efficiency ratios could be used to measure how well Ensysce Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Some institutional investors establish a significant position in pink sheets such as Ensysce Biosciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Ensysce Biosciences, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Ensysce Biosciences Workforce Comparison
Ensysce Biosciences is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 224. Ensysce Biosciences holds roughly 6.0 in number of employees claiming about 2.68% of stocks in Biotechnology industry.
Ensysce Biosciences Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Ensysce Biosciences Price Series Summation is a cross summation of Ensysce Biosciences price series and its benchmark/peer.
Ensysce Biosciences Notable Stakeholders
An Ensysce Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ensysce Biosciences often face trade-offs trying to please all of them. Ensysce Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ensysce Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Geoff Birkett | Chief Officer | Profile | |
| MSE MBA | Chief Officer | Profile | |
| Lynn Kirkpatrick | CEO Director | Profile | |
| Jeffrey Millard | Chief Officer | Profile | |
| William Schmidt | Chief Officer | Profile | |
| David Humphrey | Chief Officer | Profile |
About Ensysce Biosciences Management Performance
The success or failure of an entity such as Ensysce Biosciences often depends on how effective the management is. Ensysce Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ensysce management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ensysce management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. Ensysce Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Please note, the imprecision that can be found in Ensysce Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Ensysce Biosciences. Check Ensysce Biosciences' Beneish M Score to see the likelihood of Ensysce Biosciences' management manipulating its earnings.
Ensysce Biosciences Workforce Analysis
Traditionally, organizations such as Ensysce Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ensysce Biosciences within its industry.Ensysce Biosciences Manpower Efficiency
Return on Ensysce Biosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 4.9M | |
| Net Loss Per Executive | 4.9M |
Additional Tools for Ensysce Pink Sheet Analysis
When running Ensysce Biosciences' price analysis, check to measure Ensysce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ensysce Biosciences is operating at the current time. Most of Ensysce Biosciences' value examination focuses on studying past and present price action to predict the probability of Ensysce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ensysce Biosciences' price. Additionally, you may evaluate how the addition of Ensysce Biosciences to your portfolios can decrease your overall portfolio volatility.